- Previous Close
4.0000 - Open
4.0350 - Bid --
- Ask 4.0000 x 200
- Day's Range
3.8400 - 4.0350 - 52 Week Range
3.5000 - 12.3000 - Volume
13,539 - Avg. Volume
46,418 - Market Cap (intraday)
77.822M - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-2.6400 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
19.66
Camp4 Therapeutics Corporation, a clinical-stage biopharmaceutical company, discovers and develops regulatory RNA-based therapeutics to treat a range of genetic diseases. Its lead product candidate is CMP-CPS-001 for the treatment of urea cycle disorders. The company also develops CMP-SYNGAP to treat synaptic Ras GTPase activating protein 1-related disorders. Camp4 Therapeutics Corporation was formerly known as Marauder Therapeutics, Inc. and changed its name to Camp4 Therapeutics Corporation in March 2018. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
www.camp4tx.comRecent News: CAMP
View MorePerformance Overview: CAMP
Trailing total returns as of 4/1/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CAMP
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CAMP
View MoreValuation Measures
Market Cap
78.53M
Enterprise Value
85.45M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
322.11
Price/Book (mrq)
--
Enterprise Value/Revenue
315.31
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-49.80%
Return on Equity (ttm)
-101.99%
Revenue (ttm)
652k
Net Income Avi to Common (ttm)
-51.79M
Diluted EPS (ttm)
-2.6400
Balance Sheet and Cash Flow
Total Cash (mrq)
64.04M
Total Debt/Equity (mrq)
13.83%
Levered Free Cash Flow (ttm)
-26.54M